The Study of Active Monitoring in Sweden (SAMS): A randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer

References

• Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868–78.
   PubMed Web of Science ®Google Scholar
• Bratt O, Berglund A, Adolfsson J, Johansson JE, Tornblom M, Stattin P. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden. Scand J Urol Nephrol 2010;44:384–90.
   PubMed Web of Science ®Google Scholar
• Prostate cancer. National quality report for the year of diagnosis 2011 from the National Prostate Cancer Register (NPCR). 2012. Available from http://www.cancercentrum.se/Global/RCCUppsalaOrebro/V%c3%a5rdprocesser/urologi/prostatacancer/rapporter/20121211_NPCR_ENG_Rapport_2011.pdf.
   Google Scholar
• Rider JR, Sandin F, Andren O, Wiklund P, Hugosson J, Stattin P. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol 2013;63:88–96.
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–13.
   PubMed Web of Science ®Google Scholar
• Johnstone PA, Rossi PJ, Jani AB, Master V. “Insignificant” prostate cancer on biopsy: pathologic results from subsequent radical prostatectomy. Prostate Cancer Prostatic Dis 2007;10:237–41.
   PubMed Web of Science ®Google Scholar
• Suardi N, Capitanio U, Chun FK, Graefen M, Perrotte P, Schlomm T, et al. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer 2008;113:2068–72.
   PubMed Web of Science ®Google Scholar
• Smaldone MC, Cowan JE, Carroll PR, Davies BJ. Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort. J Urol 2010;183:138–43.
   PubMed Web of Science ®Google Scholar
• El Hajj A, Ploussard G, de la Taille A, Allory Y, Vordos D, Hoznek A, et al. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS). BJU Int 2012;111:53–9.
   PubMed Web of Science ®Google Scholar
• Dall'era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62:976–83.
   PubMed Web of Science ®Google Scholar
• Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, et al. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 2012;110:1672–7.
   PubMed Web of Science ®Google Scholar
• Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Goteborg randomised population-based prostate cancer screening trial. Eur Urol 2013;63:101–7.
   PubMed Web of Science ®Google Scholar
• Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126–31.
   PubMed Web of Science ®Google Scholar
• Selvadurai ED, Singhera M, Thomas K, Mohammed K, Woode-Amissah R, Horwich A, et al. Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol 2013; Epub ahead of print.
   PubMedGoogle Scholar
• Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, et al. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res 2012;18:5471–8.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2011;29:228–34.
   PubMed Web of Science ®Google Scholar
• Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with Gleason score (GS) ≤ 6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 2012;36:1346–52.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Speakman M. Should we really consider Gleason 6 prostate cancer? BJU Int 2012;109:645–6.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Barry JM, Burke W, Col NF, Corso PS, Dodson E, et al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med 2012;156:591–5.
   PubMed Web of Science ®Google Scholar
• Fu Q, Moul JW, Banez LL, Sun L, Mouraviev V, Xie D, et al. Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer. Med Oncol 2012;29:3339–44.
   PubMed Web of Science ®Google Scholar
• Barzell WE, Melamed MR, Cathcart P, Moore CM, Ahmed HU, Emberton M. Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer. J Urol 2012;188:762–7.
   PubMed Web of Science ®Google Scholar
• Duffield AS, Lee TK, Miyamoto H, Carter HB, Epstein JI. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol 2009;182:2274–8.
   PubMed Web of Science ®Google Scholar
• Mabjeesh NJ, Lidawi G, Chen J, German L, Matzkin H. High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy. BJU Int 2012;110:993–7.
   PubMed Web of Science ®Google Scholar
• Venkitaraman R, Norman A, Woode-Amissah R, Fisher C, Dearnaley D, Horwich A, et al. Predictors of histological disease progression in untreated, localized prostate cancer. J Urol 2007;178:833–7.
   PubMed Web of Science ®Google Scholar
• Visapaa H, Hotakainen K, Lundin J, Ala-Opas M, Stenman UH. The proportion of free PSA and upgrading of biopsy Gleason score after radical prostatectomy. Urol Int 2010;84:378–81.
   PubMed Web of Science ®Google Scholar
• Magheli A, Hinz S, Hege C, Stephan C, Jung K, Miller K, et al. Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. J Urol 2010;183:126–31.
   PubMed Web of Science ®Google Scholar
• Vargas HA, Akin O, Afaq A, Goldman D, Zheng J, Moskowitz CS, et al. Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol 2012;188:1732–8.
   PubMed Web of Science ®Google Scholar
• Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2013;63:125–40.
   PubMed Web of Science ®Google Scholar
• Sonn GA, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol 2013;189:86–92.
   PubMed Web of Science ®Google Scholar
• Quentin M, Blondin D, Klasen J, Schek J, Buchbender C, Miese FR, et al. Evaluation of a structured report of functional prostate magnetic resonance imaging in patients with suspicion for prostate cancer or under active surveillance. Urol Int 2012;89:25–9.
   PubMed Web of Science ®Google Scholar
• Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011;185:126–31.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98:1128–33.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Lee RK, Chung DE, Te AE, Scherr DS, Tewari A, et al. Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5alpha-reductase inhibitors markedly enhances the detection rate of prostate cancer. J Urol 2012;188:757–61.
   PubMed Web of Science ®Google Scholar
• Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol 2006;176:868–74.
   PubMed Web of Science ®Google Scholar
• Finelli A, Trottier G, Lawrentschuk N, Sowerby R, Zlotta AR, Radomski L, et al. Impact of 5alpha-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol 2011;59:509–14.
   PubMed Web of Science ®Google Scholar
• Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet 2012;379:1103–11.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–24.
   PubMed Web of Science ®Google Scholar
• Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5alpha-reductase inhibitors for prostate-cancer prevention. N Engl J Med 2011;365:97–9.
   PubMed Web of Science ®Google Scholar
• Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013;63:597–603.
   PubMed Web of Science ®Google Scholar
• Johansson E, Steineck G, Holmberg L, Johansson JE, Nyberg T, Ruutu M, et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol 2011;12:891–9.
   PubMed Web of Science ®Google Scholar